NYSE:CIHealthcare
A Look At Cigna Group’s Valuation After PBM Reform Progress And New CEO Announcement
Recent analyst commentary around pharmacy benefit manager reform, a rebate-free model and a leadership change has put Cigna Group (CI) back in focus for investors watching how regulatory shifts shape earnings visibility.
See our latest analysis for Cigna Group.
Those regulatory updates and the CEO transition are playing out against a softer trading backdrop, with a 30 day share price return of an 8.09% decline and a 1 year total shareholder return of a 17.76% loss suggesting momentum has...